Loading...
•
Sep 30, 2020
Amneal Q3 2020 Earnings Report
Amneal reported strong third quarter results, demonstrating the effectiveness of their Amneal 2.0 strategy and resilience amidst the COVID-19 pandemic.
Key Takeaways
Amneal Pharmaceuticals, Inc. reported a net revenue of $519 million for Q3 2020, a 37% increase compared to Q3 2019. The company's GAAP net loss was $(9) million, with a diluted loss per share of $(0.06). Adjusted net income was $49 million, with an adjusted EBITDA of $114 million and adjusted diluted EPS of $0.16.
Net revenue increased by 37% to $519 million compared to the prior year.
GAAP net loss was $(9) million, an improvement from the prior year's net loss of $(265) million.
Adjusted EBITDA increased by 60% to $114 million compared to the prior year.
The company updated its full-year 2020 financial outlook with increased expectations for net revenue, adjusted EBITDA, and adjusted diluted EPS.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal is updating its previously provided 2020 guidance.
Positive Outlook
- Net revenue is expected to be between $1,950 million and $2,000 million.
- Adjusted gross margin is expected to be between 41% and 42%.
- Adjusted EBITDA is expected to be between $430 million and $460 million.
- Adjusted diluted EPS is expected to be between $0.55 and $0.65.
- Operating cash flow is expected to be between $170 million and $220 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income